Top Biotech Companies in Minneapolis, MN (31)
Cell Culture Company is a biotech organization located in Minneapolis, MN. Headquarters include corporate offices, manufacturing operations, regulated clean room spaces, and a distribution center. C3 offers tools and services to the therapeutic, cell therapy, diagnostic, genomic, animal health, food safety and research industries. C3 team members are experts in aseptic technique, bioreactor manufacturing, cell culture, purification, quality control, analytics and...
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers...
Bio-Techne's Top Stability & Growth Strengths
Profitability: Adjusted EPS and operating margins expanded despite muted top-line trends, including a 31.1% adjusted operating margin in the most recent quarter. Cost and productivity actions supported margin improvement even as sales were flat year over year.
Strong Market Position & Advantage: Leadership in niches such as immunoassays and high-quality proteins (R&D Systems), RNA-ISH (RNAscope), and automated protein analysis (ProteinSimple) underpins competitive strength. In-house manufacturing control over most reagents reinforces quality and consistency across core categories.
Future-Ready Strategy: Focus on cell therapy, proteomic instrumentation, spatial biology, and precision diagnostics has expanded as a share of revenue and aligns with high-growth workflows. Acquisitions and strategic stakes (e.g., Lunaphore, Wilson Wolf/ScaleReady) position the portfolio for emerging demand.
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Smith & Nephew's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show mid-single-digit underlying growth through 2024–2025, with management reiterating guidance for continued growth in 2026. Early 2026 updates indicate broad-based contributions across units despite some subsegment variability.
Profitability: Trading profit and margins improved, supported by execution of the 12‑Point Plan and the transition to the RISE strategy. Management is guiding to further profit growth alongside higher returns.
Healthy Cash Flow: Free cash flow strengthened in 2025 with guidance for robust generation in 2026. Share repurchases completed and newly announced buybacks signal confidence and disciplined capital allocation.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Pace® works with organizations of all types, providing the science to ensure our air, water, therapies, and more are safe for use. Learn more about our laboratory services at PACELABS.com.
Pace Labs's Top Stability & Growth Strengths
Strong Market Position & Advantage: Pace is widely characterized as a U.S. leader in environmental testing with standout PFAS credentials, including multi‑method DoD accreditations and repeated industry recognition. Life‑sciences credibility is evidenced by FDA‑inspected sites and Top CDMO recognition, with leadership most pronounced in specific U.S. niches.
Market Expansion: The company has materially expanded its footprint via acquisitions (e.g., Alpha Analytical, ESL, Agra) and site adds, bringing the U.S. network to roughly 125–127 labs and service centers by late 2024. Life‑sciences additions (Curia NJ, Catalent RTP) and new centers and facilities further extend reach and capacity.
Future-Ready Strategy: Capacity investments target high‑growth areas such as sterile fill‑finish, biologics, gene therapy, and advanced PFAS methods, alongside positive FDA inspections and new centers of excellence. Backing for expansions, including a state‑supported buildout, indicates preparation for rising regulated testing and advanced therapy demand.
A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $12 billion and more than 44,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve...
Ecolab's Top Stability & Growth Strengths
Profitability: Record sales, earnings per share, and operating margins in 2024 and 2025 indicate sustained margin improvement. Feedback suggests continued expansion is expected in 2026 supported by pricing discipline, productivity, and higher‑margin services.
Strong Market Position & Advantage: Ecolab is consistently characterized as a global leader across water, hygiene, and infection prevention with broad industry reach and high customer retention. Feedback suggests external accolades and large-scale operations reinforce a durable competitive moat.
Innovation-Driven Growth: Expansion into high-growth areas like hyperscale data centers, microelectronics, and life sciences is supported by acquisitions and digital services. Feedback suggests AI-enabled analytics, performance-based contracts, and a growing backlog are fueling future growth.
Vireo Health is a physician-led company dedicated to providing patients with best-in-class cannabis-based products and high quality care
Luminary Therapeutic is a cancer research center focus on helping more patients faster.
Celcuity transform care for patients with cancer or autoimmune disease.
Emerging Therapy Solutions® (ETS) was founded in 2018 by industry veterans of managed care solutions, healthcare biotech and transplant to help healthcare payers manage the risks associated with high-cost therapies for rare and complex conditions. ETS acquired LifeTrac in 2020, bringing over 30 years of experience in bone marrow and solid organ transplants, plus provider relationships and agreements, to complement Emerging...
NMDP is a global nonprofit leader in cell therapy and blood stem cell and bone marrow transplantation. Entrusted to operate the federally authorized C.W. Bill Young Cell Transplantation Program, they advance research and provide life-saving care to patients with blood cancers and disorders.
28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today’s neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human...
Cardiovascular Systems, Inc. (CSI) is committed to providing innovative solutions for the revascularization of patients with complex coronary and peripheral artery disease (PAD). Our primary focus is helping physicians conquer even the most difficult disease states, including the challenge of arterial calcium for the millions who suffer from PAD and Complex PCI. CSI is committed to clinical rigor, constant innovation,...
Tychon Bioscience is a biotechnology company commercializing adaptive immunotherapy technology.
American Preclinical Services is a research company that offers biocompatibility and surgical research services.
The Atlanta Biological brand of serum & media products is now rebranded as R&D Systems. The product quality, selection & catalog numbers will remain the same.
Discovery Genomics, Inc. (DGI) was founded in 2000 and became operational in January 2002.
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We...
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
